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Background: There is limited data on chronic insomnia in Operation Enduring Freedom/Operation Iraqi
Freedom (OEF/OIF) veterans, in whom post-traumatic stress disorder (PTSD) and mild traumatic brain
injury (mTBI) often co-exist. Our aim was to compare sleep characteristics of three groups of OEF/OIF vet-
erans: (1) healthy sleepers (HS), (2) those with insomnia associated with PTSD and mTBI (PTSD–mTBI),
and (3) those with insomnia associated with PTSD alone.
Methods: Consecutive veterans with insomnia complaints (>6 months) were recruited over 6 months
from the Miami VA Post Deployment clinic. Participants completed a sleep disorders clinical interview,
medical history, and questionnaires about insomnia, sleepiness, pain, fatigue, depression, PTSD, and
health-related quality of life. They underwent polysomnography (PSG) with 2 weeks of actigraphy
(ACT) and sleep diaries.
Results: There were no differences in demographics or most questionnaire responses between PTSD and
PTSD–mTBI groups. Subjective daytime sleepiness was significantly greater in PTSD–mTBI subjects com-
pared with HS and PTSD participants. Significant co-morbid sleep disorders were noted in insomnia
patients. PSG and ACT wake after sleep onset was significantly shorter in PTSD–mTBI subjects as com-
pared with PTSD participants.
Conclusion: Insomnia patients with PTSD–mTBI were subjectively sleepier despite spending less time
awake during the night than PTSD subjects, possibly as a consequence of head trauma.
Published by Elsevier B.V.
1. Introduction
Insomnia, frequent difficulty with falling or staying sleep or
early morning awakenings resulting in daytime impairments, is
one of the most common complaints reported by Operation Endur-
ing Freedom/Operation Iraqi Freedom (OEF/OIF) veterans at post-
deployment clinics [1–4]. Most patients recover fully within 3–
6 months after mild traumatic brain injury (mTBI); however, 10–
15% of patients have persistent post-concussive symptoms (head-
aches, anxiety, depression, disequilibrium, cognitive complaints,
and insomnia) [5]. Acutely, sleep disruption from insomnia or
other sleep disorders may mediate entrenchment of post-trau-
matic stress disorder (PTSD) and post-concussive symptoms by
impeding restorative processes occurring during undisturbed sleep
[6,7]. Furthermore, insomnia after mTBI or PTSD may initiate or
exacerbate psychiatric problems, behaviour, memory and social
functioning, and negatively impact rehabilitative treatments.
Insomnia with short sleep duration has also been associated with
worse quality of life, increased health-care costs, increased risk
for hypertension, diabetes and all-cause mortality [8–11].
Although PTSD and mTBI often co-exist in this veteran population
[3], there is limited information about clinical correlates and
insomnia characteristics in OEF/OIF veterans with PTSD and mTBI
[1,2,4,12,13].
1.1. Insomnia and mTBI
Chronic insomnia, insomnia lasting for more than 1 month, can
be the heralding symptom of PTSD and may develop after mTBI
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[2,7]. The prevalence of insomnia complaints after mTBI ranges
widely from 21% to 93% [3–5,14,15]. Insomnia after mTBI is com-
plicated and multifactorial, possibly resulting from injury to cere-
bral structures responsible for regulating sleep, co-morbid
affective and anxiety disorders, post-traumatic pain, and the side
effects of multiple medications used to treat some of these co-mor-
bid conditions [7]. Polysomnography (PSG) studies in insomnia
associated with mTBI have shown variable abnormalities including
sleep macrostructure disturbances correlating with subjective
complaints. These include a greater proportion of ‘light sleep’,
higher sleep fragmentation with greater wake after sleep onset
(WASO) and increased number of awakenings as compared with
healthy sleepers (HSs) [16–18]. Actigraphic studies in mTBI are
limited but have corroborated these PSG findings and demon-
strated greater time spent in bed and increased total sleep time
(TST) as compared with controls [18]. While comparisons between
these studies are difficult due to methodological differences, all of
these findings suggest sleep instability after mTBI.
1.2. Insomnia and PTSD
PTSD is characterised by three symptom clusters (re-experienc-
ing, avoidance, and hyperarousal) that can all contribute to insom-
nia. Recurring military-related nightmares, avoiding sleep because
of these, and nocturnal checking ‘safety perimeter’ behaviours (fre-
quent checking of windows and doors) in the home environment
are all incongruent with sleep initiation. PSG studies demonstrat-
ing objective sleep abnormalities in PTSD have yielded inconsistent
results. A meta-analysis of 20 PSG-based studies in patients with
PTSD revealed that increased rapid eye movement (REM) density,
greater N1 sleep and decreased slow-wave sleep were seen in PTSD
patients compared with normals [19]. Other consistent findings
have involved dysfunction of REM sleep mechanisms including in-
creased phasic events (motor events) and REM sleep fragmentation
[20–23]. These abnormalities support findings of centrally mea-
sured hyperarousal during sleep in PTSD [24]. Some investigators
have found co-morbid mild sleep-disordered breathing (SDB) to
be common in patients with PTSD while others have not [23,25].
Actigraphic data in PTSD is limited but a few studies have used it
to estimate TST and awakenings in veterans with PTSD [26].
Although young veterans may suffer from a wide variety of
sleep complaints including insomnia, snoring and nocturnal
behaviours, the necessity for a comprehensive sleep evaluation is
not well established. Among these sleep disorders, insomnia is
the most prevalent [2]. Improved understanding of the nature of
insomnia and its clinical correlates in OEF/OIF veterans may help
identify potential interventional targets (behavioural and pharma-
cological) and determine need for sleep testing. Most studies of
returning OEF/OIF veterans’ sleep quality have relied on responses
to a single-item regarding sleep embedded within an instrument
measuring other outcomes (depression and PTSD) and have not
employed validated sleep questionnaires, laboratory PSG or re-
peated objective measures in home environments [2–5,13]. Self-
reported measures are problematic as lone sleepers may lack
awareness of occult sleep disturbances. Repeated home assess-
ments may be useful as persons with insomnia may become condi-
tioned to their bedroom environment and have high night-to-night
variability [27]. A single night of laboratory PSGs may fail to reveal
these abnormalities. In this study, we measure the sleep of combat
veterans subjectively reporting chronic insomnia symptoms (i.e.,
difficulty falling or staying asleep or early morning awakenings
for at least 6 months with daytime repercussions) not attributable
to another primary sleep disorder (i.e., significant sleep apnoea or
restless legs syndrome) using comprehensive sleep evaluations.
The primary aim of this prospective study is to assess sleep param-
eters using validated questionnaires and structured clinical inter-
views for sleep disorders, PSG, actigraphy (ACT), and sleep diaries
(SDs). These parameters were compared amongst veterans with
PTSD, veterans with PTSD–mTBI, and HSs. We hypothesised that
veterans with PTSD–mTBI would have more severe insomnia com-
plaints, show greater PSG and ACT sleep fragmentation and report
worse quality of life compared with veterans with PTSD alone and
HSs.
2. Methods
2.1. PTSD and PTSD–mTBI Subjects
Subjects with PTSD or PTSD–mTBI were consecutive OEF/OIF
veterans with insomnia complaints (P6 months) recruited from
the Miami VA HealthCare System Post Deployment clinic during
routine clinical visits between 1st June and 31st December 2009
(control subjects are described in next section). In this study,
insomnia was defined as difficulty initiating or maintaining sleep
or with early morning awakenings on more than three nights of
the week for at least 6 months despite adequate opportunity to
sleep. Subjects also had to endorse at least one accompanying day-
time symptom (fatigue, sleepiness, mood disturbance, poor moti-
vation, concentration difficulties, or worries about sleep) [28].
Sleep pattern was documented during 2 weeks of SDs. Inclusion
criteria were (1) adults aged 18–50 years, (2) OEF/OIF veterans
with combat exposure with stable physical and mental health,
and (3) English literacy at grade 5 or higher. Subjects were ex-
cluded if (1) prior to deployment, they had history of sleep disor-
der, psychiatric disorder or a TBI, (2) suffered penetrating,
moderate or severe TBI, (3) had active substance abuse, (4) had
insomnia secondary to pain or another primary sleep disorder
(moderate to severe SDB, periodic limb movement disorder or
moderate to severe restless legs syndrome), (5) were using medica-
tion causing insomnia (i.e., stimulant medications), or (6) failed to
complete all study assessments. Subjects using stable doses (un-
changed dosage for 3 months preceding enrollment) of hypnotic
medications were not excluded from the study if their insomnia
complaints persisted despite medication use.
2.2. Inclusion criteria for the control group
Consecutive OEF/OIF veterans were screened for sleep disorders
and typical sleep duration during their routine well visits to the
Miami VA Health Care System Post Deployment primary care pro-
vider. They were required to be in good physical andmental health,
with no sleep complaints, free of medications influencing sleep and
having sufficient, regular sleeping hours. Thirty-six veterans were
screened with a brief structured clinical interview for sleep disor-
ders and review of their medical record for inclusion and exclusion
criteria. Six HSs were identified.
The study was approved by the Bruce W. Carter Department of
Veterans Affair Medical Center institutional review board and writ-
ten patient consent was obtained from all study participants.
2.3. Procedure
All subjects were scheduled for a 4-h baseline study visit, where
they completed a structured clinical interview for sleep disorders,
a full neurological examination, comprehensive lifetime concus-
sion history and standardised instruments for assessment of men-
tal health, sleep disorders, and health-related quality of life
(HRQOL), as described below. Demographic characteristics, medi-
cation use (including those prescribed for insomnia) and military
service details (including exposure to traumatic events such as
explosions, history of head trauma or other injuries occurring
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during deployment) were obtained through questionnaires and re-
view of medical records. Information was corroborated by DD214s
forms, which provide information about deployment length, mili-
tary occupation, and discharge.
2.4. Clinical assessment of insomnia and other sleep disorders
Subjects completed the Duke Structured Interview for Sleep
Disorders (DSISD), which is derived from the International Classifi-
cation of Sleep Disorders (ICSD-2) [28]. Using this instrument al-
lowed the identification of insomnia subtype and other co-
morbid sleep disorders. When available, bed partners helped cor-
roborate reports.
2.5. Self-report measures
2.5.1. Post-traumatic stress checklist-military version (PCL-M)
The post-traumatic stress checklist-military version (PCL-M) is
a 17-item National Center for PTSD Checklist used to assess the
severity of avoidance, hyperarousal, and intrusion symptoms
[29]. The PTSD checklist is based on well-validated case definitions
used in veteran and military populations [1]. The PCL-M scores
range from 0 to 85, with higher scores indicative of more severe
symptoms. Participants were defined as having PTSD symptoms
if they endorsed at least three avoidance symptoms, two hyper-
arousal symptoms and one intrusion symptom at ‘moderate’ or
higher levels and scored at least 50 on the PTSD checklist, indica-
tive of significant distress.
2.5.2. Insomnia severity index (ISI)
The insomnia severity index (ISI) is a brief, seven-item instru-
ment measuring the patient’s perception of his or her insomnia.
Items assess the severity of sleep onset and sleep maintenance dif-
ficulties (both nocturnal and early morning awakenings), satisfac-
tion with current sleep pattern, interference with daily
functioning, noticeability of impairment attributed to the sleep
problem, and degree of distress or concern caused by the sleep
problem. The total scores range from 0 to 28, with a cut-off score
of 8 suggestive of mild clinical insomnia and higher scores consis-
tent with worse insomnia symptoms. Its internal consistency, con-
current validity, and sensitivity to clinical improvements are well
established [30].
2.5.3. Epworth sleepiness scale (ESS)
The Epworth sleepiness scale (ESS) is a measure of subjective
daytime sleepiness used for patients with SDB. Eight items are
rated on a scale of 0–3, total scores range 0–24, with higher scores
indicating a greater propensity to fall asleep in different situations.
A score P10 indicates excessive daytime sleepiness. In samples of
SDB patients, it shows high internal consistency and correlates
well with objective measures of sleep latency [31].
2.5.4. Fatigue severity scale (FSS)
The fatigue severity scale (FSS) is a nine-item scale originally
developed to capture an individual’s experience of mental or psy-
chological fatigue and how it interferes with performing daily
activities (i.e., exercise and work) over the prior week. A cut-off
score of P36 defines fatigue. It has been used and validated in di-
verse neurologic patient populations [32].
2.5.5. Beck depression inventory-II (BDI-II)
This measure consists of 21 items evaluating depressive symp-
toms experienced in the prior 2 weeks. Total scores range from 0 to
62 (0–13 no depression; 14–21 mild depression; 22–30 moderate
depression, and >30 severe depression). It is widely used and its
psychometric properties have been well documented [33].
2.5.6. Pain assessment
Participants were asked to rate ‘‘How much does pain interfere
with your nightly ability to begin or continue sleeping?’’ on a 100-
mm visual analogue scale. One end of the scale was labelled ‘‘‘not
at all’’ and the other end labelled ‘‘extremely’’.
2.5.7. Short Form-36 (SF-36)
The Short Form-36 (SF-36) is a 36-item quality-of-life measure
that assesses eight domains: (1) physical functioning; (2) role lim-
itation due to physical health problems (role physical); (3) bodily
pain; (4) general health perceptions; (5) vitality; (6) social func-
tioning; (7) role limitations due to emotional health problems (role
emotional); and (8) mental health [34]. Physical function and role
physical scales best distinguish between groups differing in
severity of chronic medical conditions and have the purest inter-
pretation with regard to physical health; mental health and
role-emotional scales best distinguish between groups differing
in severity of psychiatric disorders and have the purest interpreta-
tion with regard to mental health. Social function, vitality, and gen-
eral health perception scales measure both physical, and mental
health status [34]. All health measures were scored on scales of
0–100, with higher scores indicating better health. The SF-36 has
been carefully tested, validated, and used in patients with chronic
diseases including chronic insomnia [8,35].
2.6. Clinical assessment of traumatic brain injury
All participants underwent a full neurological exam by a board-
certified neurologist experienced with TBI populations (DMW). A
lifetime concussion history was taken including history of child-
hood accidents, falls, motor vehicle accidents, and participation
in contact sports. Participants completed questionnaires concern-
ing head trauma occurring during deployment including (1) loss
of consciousness and post-traumatic amnesia duration, (2) aetiol-
ogy, (3) post-concussion symptoms, (4) date, and (5) number of
events. Mild TBI diagnosis was made per American Academy of
Neurology Grade III concussion guidelines, which require loss of
consciousness (LOC) 630 min [36]. When available, mTBI diagnosis
was corroborated with documentation from active military re-
cords. As military medical records of a TBI incident were some-
times not available, the participant’s account of the event was
used to satisfy criteria.
2.7. Nocturnal PSG
A standard montage was used, including electroencephalo-
graphic (EEG), electromyographic (EMG), and electrooculographic
(EOG) monitoring for an in-lab overnight video-PSG. Measures of
airflow and EMG of the legs and arms were taken to detect SDB
and limb movements. Participants were asked to return to the
sleep lab for a second night of evaluation within a week.
The second PSG was used to determine sleep stages, arousals
and sleep-related events and were scored according to established
American Academy of Sleep Medicine criteria by an experienced
technician blinded to subject’s group assignment [37]. Sleep onset
latency (SOL) was measured as the time between lights out to the
first 10 min of persistent sleep. Awakenings were counted when
two consecutive epochs were scored as wake. REM latency repre-
sents the time between sleep onset and the first REM episode
noted.
Upon awakening after each night of PSG, participants were
asked to complete a short questionnaire approximating their time
in bed (TIB), TST, SOL, and WASO and comparing their sleep quality
in the sleep lab to their sleep at home.
A preliminary analysis (Wilcoxon signed-ranks test) on PSG
measures (sleep efficiency (SE), SOL, and WASO) was computed
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to verify whether participants slept differently in the sleep labora-
tory on night 1 compared with night 2 (first-night effect). Neither
insomnia group had significant differences in SOL between PSG
nights, but the HS group had significantly higher SOL on night 1.
Both HS and PTSD–mTBI participants had significantly lower SE
and higher WASO on night 1, suggesting that they had a ‘‘first night
effect’’. Hence, as is commonly done in sleep research, only night 2
was analysed further.
2.8. ACT/home SDs
On the second night of PSG, participants were given an acti-
graph (Mini Mitter-Respironics Inc., Bend, OR, USA; Actiwatch
Spectrum) to wear on the non-dominant wrist. An actigraph is a
wristwatch-like device that records movement through an acceler-
ometer and has a photodiode for detecting light intensity exposure.
It can be used to infer whether the subject is asleep or awake. PSG
and ACT software were synchronised to correlate sleep variables
measured by both assessments. Participants were asked to wear
the actigraph for 14 consecutive days and nights. In addition, they
were asked to maintain an SD, which they were instructed to fill
out every morning upon awakening, noting times they went to
bed, number and length of nocturnal awakenings, morning wake
up times, quality of the previous night’s sleep and any naps taken
during the day. At the end of the 2-week study period, the acti-
graph and SD were returned to the sleep centre.
ACT data were downloaded and analysed using Actiware 5.0
software and Actiwatch Firmware version 01.01.0007 (Mini Mit-
ter-Respironics Inc., Bend, OR, USA) by an experienced scorer
(DMW). Data were averaged into 1-min epochs. The daily primary
sleep periods were calculated manually in conjunction with SD
data and actigraphically recorded light information. The wake
threshold value (i.e., the number of activity counts used to define
wake) was set to medium sensitivity of 40.0 activity counts per
epoch. The sleep onset, offset, and ACT–TST were recorded and
SE was calculated. ACT–SOL was defined as the start of the first
10 min of consecutive sleep after bedtime. SD and photodiode
‘lights off’ data were used to determine each bedtime. Similarly,
sleep offset was defined as the end of the last 10 min of consecu-
tive sleep prior to wake time.
Measures of sleep fragmentation on ACT were: (1) total WASO,
(2) number of nocturnal awakenings lasting at least 5 min
(NAP 5 min) during the primary sleep interval, and (3) the sleep
fragmentation index (the ratio of the number of groups of consec-
utive epochs of sleep to the total number of sleep epochs such that
a greater index indicates less continuous sleep).
Home SDs provided the following subjective measurements of
participant’s sleep: TIB (SD–TIB), TST (SD–TST: sleep duration in
the last 24 h), SE (SD–SE), SOL (SD–SOL), WASO (SD–WASO), num-
ber of nocturnal awakenings and sleep quality (Likert scale 1 ‘very
poor’’’ to 5 ‘excellent’).
2.9. Data analysis
Clinical characteristics, questionnaires, and PSG variables were
compared between the PTSD, PTSD–mTBI, and HS groups. Results
are presented as mean ± standard deviation or median (interquar-
tile range) according to their normality distribution. Groups were
compared by Fisher–Freeman–Halton exact test, analysis of vari-
ance (ANOVA), and Kruskal–Wallis for categorical and continuous
(parametric or non-parametric) data, respectively. If significant dif-
ferences were shown, they were followed by a pair-wise Fisher’s
exact test with Bonferroni’s correction and post hoc analyses with
Tukey’s test and Conover–Inman’s test, respectively. Cliff’s delta
(d) statistic was applied to pair-wise comparisons to estimate
non-parametric effect sizes. It describes the percentage of non-
overlap between two sample distributions, where the sign reflects
the direction of the comparison (negative when the second com-
parison group has higher values than the first) [38]. Hence, a
d = 0.75 for a comparison A versus B means a 75% non-overlap
(25% overlap) between samples distributions where the first group
A has greater values than those of group B. Therefore, d ranges from
0 (complete overlap) to ±1 (no overlap) [38–40]. Cohen’s interpre-
tations of the effect size index d in terms of the non-overlap be-
tween two normal distributions provide a direct bridge between
d and Cliff’s delta (d) so that a d effect size of 0.20 (small) will have
a d of 0.147, a d effect size of 0.50 (medium) corresponds to a d of
0.33 and a d effect size of 0.80 (large) corresponds to a d of 0.474
[38]. Cliff’s delta statistics has been shown to be a robust and reli-
able effect size measure when parametric assumptions cannot be
met [38–40].
Spearman’s rank correlation was used to determine relation-
ships between TST, SE, SOL, and WASO between PSG, SD, and
ACT recordings on the second PSG night. Statistical significance
was assumed for two-tailed p-values <0.05. Statistical analyses
were performed with Statistical Package for the Social Sciences
(SPSS) Statistics 17.0 (SPSS, Chicago, IL, USA), StatsDirect 2.7.2
(StatsDirect Ltd., UK), and ViSta 6.4 (Visual Statistics System, Cha-
pel Hill, NC, USA) with an Effect Size Calculator plugin (ES-Calc.)
[40].
3. Results
3.1. Demographics and clinical characteristics
Thirty-eight male veterans were recruited into the study. Eight
were excluded (two for moderate–severe obstructive sleep apnoea,
one for severe restless legs symptoms, one for paradoxical insom-
nia, one for history of mTBI predating deployment, and three failed
to complete all procedures). Six HS, nine PTSD patients, and 15
PTSD–mTBI patients completed the study. The mean age of the
30 subjects was 31 ± 7 years and the mean body mass index
(BMI) was 27 ± 4 kg m2. Subject ethnicity was predominantly His-
panic (63%), followed by 23% Caucasian, 7% Asian, and 7% African–
American. There were no significant differences between the
groups in mean age, mean education years, mean time since
deployment completion, or mean length or number of deploy-
ments. Employment, marital status, sleeping arrangement, and cof-
fee, alcohol, or tobacco consumption distribution also did not differ
between the groups (Table 1).
The PTSD and PTSD–mTBI groups used a significantly higher
mean number of hypnotics when compared with HS (Table 1).
All insomnia patients were using at least one psychotropic medica-
tion. The PTSD group had a significantly higher use of analgesics
compared with the HS group (78% vs. 0%, p = 0.021, Fisher’s exact
test with Bonferroni’s correction). There was no significant differ-
ence between PTSD and PTSD–mTBI groups in medication regimen.
The mean number of mTBIs was 2.1 ± 1.3 events. Eighty-two
percent of mTBI reported LOC for less than 5 min. Aetiologies of
mTBIs were blast injury in 15% and mixed (blast followed by motor
vehicle accident, shrapnel injury or fall) in 85%. All PTSD–mTBI
subjects had non-contrast magnetic resonance imaging (1.5 Tesla)
which was unremarkable for intracranial abnormalities.
3.2. Questionnaires
The HS group had significantly lower median scores on ques-
tionnaires concerning insomnia symptoms, fatigue, pain, depres-
sion, and PTSD and significantly higher HRQOL scores compared
with both insomnia groups (Table 2). Insomnia severity proportion
was not significantly different in the PTSD and PTSD–mTBI groups
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with 44% and 60% reporting moderate insomnia and 56% and 40%
reporting severe insomnia symptoms, respectively. Seventy-eight
percent of PTSD and 80% of PTSD–mTBI subjects complained of ‘se-
vere’ or ‘very severe’ sleep-initiation difficulties; 89% of PTSD and
87% of PTSD–mTBI complained of ‘severe’ or ‘very severe’ sleep-
maintenance difficulties; and 44% of PTSD and 53% of PTSD–mTBI
complained of ‘severe’ or ‘very severe’ problems with early awak-
enings. The median ESS score of the PTSD–mTBI group (14 (inter-
quartile range, IQR, 9)) was significantly greater than that of the
PTSD (6 (IQR 7)) and HS (5 (IQR 3)) groups. The prevalence of day-
time sleepiness (ESSP10) in the HS, PTSD, and PTSD–mTBI groups
was 0%, 33%, and 60%, respectively. None of the HSs reported sig-
nificant daytime fatigue (FSS P36) as compared with 89% and
73% of the PTSD and PTSD–mTBI groups, respectively. All patients
with PTSD reported co-morbid depressive symptoms. Distribution
of depression symptom severity between the PTSD and PTSD–mTBI
groups was not significantly different with 22% and 20% reporting
mild depression, 22% and 40% reporting moderate depression, and
56% and 40% reporting severe depression symptoms, respectively.
There were no significant differences in any of the questionnaires’
median scores between the PTSD and PTSD–mTBI groups (Table 2).
3.3. Co-morbid sleep disorders
A variety of REM and non-REM (NREM) parasomnia events were
prevalent in the insomnia groups (Table 3). Nine subjects reported
at least one REM or NREM parasomnia. One participant reported
several incidents of zolpidem-associated parasomnia. REM sleep
behaviour disorder was detected in four patients with excessive
EMG tone noted during REM sleep associated with history of
dream-enactment complaints and sleep-related injury. All of these
patients were using selective serotonin reuptake inhibitor (SSRI)
antidepressants. Weekly nightmares were significantly more com-
mon in PTSD and PTSD–mTBI groups compared with the HS group.
Four PTSD–mTBI and three PTSD subjects had REM-related
obstructive respiratory events (REM–AHIP15). There were no sig-
nificant differences in mild SDB, parasomnias or sleep-related
movement disorders between the insomnia groups.
3.4. Polysomnography
Several differences were noted in sleep initiation and mainte-
nance measures and sleep architecture between the HS, PTSD,
and PTSD–mTBI groups (Table 4). The PTSD and PTSD–mTBI
groups’ median TST and SE were significantly lower compared with
Table 1
Data presented as means ± SD⁄ or frequency (%), as appropriate. Post hoc significance
levels are labeled as follows.
HS (n = 6) PTSD (n = 9) PTSD–mTBI (n = 15)
Demographics
Age (years)⁄ 31 ± 7 30 ± 7 31 ± 8
Education (years)⁄ 14 ± 2 14 ± 2 14 ± 1
BMI (kg/m2) 26 ± 1 28 ± 5 28 ± 4
Return to US (months)⁄ 29 ± 10 35 ± 19 30 ± 18
Deployments (n, %) 1.3 ± 0.5 1.3 ± 0.5 1.5 ± 0.6
Employed (n, %) 4 (67) 6 (67) 5 (33)
Full-time 2 (33) 4 (44) 4 (27)
Shift-work (n, %) 3 (50) 5 (56) 11 (73)
Marital status (n, %)
Single 2 (33) 1 (11) 6 (40)
Married 4 (67) 5 (56) 4 (27)
Divorced/separated 0 (0) 3 (33) 5 (33)
Sleeping arrangement (n, %)
Alone 2 (33) 3 (33) 11 (73)
With partner 4 (67) 6 (67) 4 (27)
Habits
Caffeine (drinks/day)⁄ 1.0 ± 0.6 2.2 ± 1.8 1.9 ± 2
Alcohol (drinks/week)⁄ 1.7 ± 1 1.6 ± 2.2 2.3 ± 3.3
Smoking (n, %)
Never 4 (67) 8 (89) 10 (67)
Past 1 (17) 0 (0) 1 (7)
Current 1 (17) 1 (11) 4 (27)
Medications (n, %)
Hypnotics (n) 0a 1.3 ± 1 1.0 ± 1
Benzodiazepines 0 3 (33) 2 (13)
Zolpidem 0 2 (22) 4 (27)
Quetiapine 0 2 (22) 5 (33)
Trazodone 0 3 (33) 1 (7)
Antidepressants
SSRIs 0 5 (56) 7 (47)
SNRIs 0 1 (11) 1 (7)
TCA 0 3 (33) 5 (33)
Bupropion 0 3 (33) 1 (7)
Stabilizers/AEDs 0 5 (56) 6 (40)
Analgesics 0b 7 (78) 6 (40)
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reup-
take inhibitor; TCA, tricyclic antidepressant; AED, antiepileptic drug.
a p < 0.01 for comparison between HS and both insomnia groups.
b p < 0.05 for comparison between HS and PTSD.
Table 2
Data presented as medians (interquartile range). Post hoc significance levels are labeled as follows:
HS (A) (n = 6) PTSD (B) (n = 9) PTSD–mTBI (C) (n = 15) Cliff’s delta (d)
AxB AxC BxC
ISI 5 (3) a 22 (5) 20 (8) 1 1 0.02
ESS 5 (3) b 6 (7) 14 (9) c 0.52 0.79 0.56
FSS 18 (7) a 46 (20) 47 (22) 1 1 0.63
BDI-II 3 (5) a 33 (26) 26 (17) 1 1 0.04
PCL-M 7 (7) a 62 (22) 56 (18) 1 1 0.05
Pain VAS 0 (1) a 30 (32) 10 (20) 0.61 0.68 0.24
SF-36 total score 95 (13) a 35 (44) 30 (25) 1 1 0.07
Physical functioning 100 (0) a 50 (40) 55 (45) 1 1 0.19
Role physical 100 (0) a 0 (100) 0 (50) 0.68 1 0.19
Bodily pain 100 (10) a 22 (36) 22 (29) 0.94 0.99 0.06
General health 95 (33) a 42 (27) 35 (30) 0.69 0.73 0.27
Vitality 85 (14) a 25 (33) 25 (25) 0.98 0.98 0.01
Social functioning 100 (0) a 38 (56) 25 (38) 1 1 0.22
Role emotional 100 (0) a 0 (50) 0 (0) 0.89 0.93 0.15
Mental health 82 (29) a 40 (40) 36 (20) 0.94 0.9 0.1
ISI, insomnia severity index; ESS, Epworth sleepiness scale; FSS, fatigue severity scale; BDI-II, Beck depression inventory-II; PCL-M, post-traumatic stress disorder checklist
military version; VAS, visual analogue scale; SF-36, Short Form-36.
a p < 0.05 for comparison between HS and both insomnia groups;
b p < 0.01 for comparison between HS and PTSD–mTBI;
c p < 0.05 for comparison between PTSD and PTSD–mTBI.
 Effect size estimate: d = 0.147 (small); d = 0.33 (moderate); and d = 0.474 (large).
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the HS group, whereas the PTSD and PTSD–mTBI groups’ median
SOL, number of awakenings, arousal index, and percentage of N1
sleep were significantly higher than those for the HS group. Per-
centage of N2, N3 (slow-wave sleep), and REM sleep was similar
in the three groups. The PTSD group had significantly longer med-
ian WASO values as compared with the PTSD–TBI group (49 (IQR
35) vs. 15 (IQR 41) min, p = 0.04, Conover–Inman’s test). Other
measures of sleep continuity (SE, arousal index and awakenings)
were similar between the insomnia groups. There were no other
significant differences in sleep architecture between the PTSD
and PTSD–mTBI groups for other PSG variables.
Second-night PSG and ACT were significantly correlated for TST,
SE, and WASO in insomnia groups and the HS group. SOL was sig-
nificantly correlated for the HS group and PTSD–mTBI but not the
PTSD group.
In the post-PSG diary, five of six HS, one of nine PTSD and three
of 15 PTSD–mTBI subjects reported similar in-lab sleep quality as
compared to home sleep quality. Seven PTSD and nine PTSD–mTBI
subjects reported improved in-lab sleep quality while one HS, one
PTSD and three PTSD–mTBI subjects reported worse in-lab sleep
quality as compared with home sleep quality. Insomnia subjects
tended to underestimate their TST and overestimate SOL and
WASO while HS subjects overestimated their TST but had close
approximation of their SOL and WASO (Table 4).
3.5. ACT and SDs
As shown in Table 4, all ACT and home SD parameters except
TIB differentiated the insomnia and HS groups. All measures of
sleep initiation and fragmentation were worse in the insomnia
groups compared with controls. The PTSD group had significantly
higher ACT–WASO as compared with the PTSD–mTBI group (62
(IQR 13) vs. 51(IQR 23) min, p = 0.03, Conover–Inman’s test).
Insomnia and HS groups remained in bed for a similar duration
but the insomnia groups slept significantly less than HSs. Although
the PTSD–mTBI group had longer median TST and TIB as compared
to the PTSD group, this did not reach statistical significance. There
were no other significant differences in ACT measures of sleep con-
tinuity (SE, NAP5 min, or fragmentation index) or in any home SD
variables between the insomnia groups.
Differences were also noted in the habitual sleep times between
the groups. Insomnia groups went to bed and woke up 1–2 h later
than the HS group. Insomnia subjects often extended their typical
weekday sleep duration on weekends by more than 2 h suggestive
of sleep deprivation or worse insomnia during the weekdays. Day-
time napping was relatively common with 33% of the PTSD and
67% PTSD–mTBI groups reporting napping at least twice weekly
in SDs. Naps ranged in duration from 20 min to 4 h but most naps
(56%) lasted 1 h or more (Table 5).
4. Discussion
4.1. Insomnia characterisation and clinical correlates
Insomnia is characterised by complaints of difficulty falling or
staying asleep or of early morning awakenings on most nights of
the week, producing troublesome daytime symptoms. Current
hypothesised pathophysiology includes the hyperarousal model
where physiological and/or cognitive arousal interfere with normal
sleep functioning. In addition, insomnia is thought to be perpetu-
ated by maladaptive sleep-related behaviours which interfere with
the underlying homoeostatic drive to sleep and the circadian tim-
ing of sleep. Chronic insomnia with short sleep duration is associ-
ated with important consequences including increased health-care
use, workplace absenteeism, risk of hypertension, diabetes, and all-
cause mortality [9–11,41]. Identifying and treating insomnia in
young veterans is paramount to prevent its harmful consequences.
To this end, the objective of this study was to provide a compre-
hensive description of chronic insomnia and its clinical correlates
in a small post-deployment clinic sample of OEF/OIF veterans with
PTSD and PTSD–mTBI compared with controls. In our study,
insomnia groups had greater fatigue, pain, PTSD, and depressive
symptoms and overall lower HRQOL.
PTSD–mTBI subjects had similar insomnia severity and sub-
types compared with PTSD subjects. Clinical variables and HRQOL
were similar between the two insomnia groups with the exception
of significantly greater subjective daytime sleepiness in the PTSD–
mTBI group. This sleepiness difference existed despite similar psy-
chiatric co-morbidity profiles, medications and sleep durations in
both insomnia groups. In addition, both groups have comparable
levels of behaviourally induced sleep restriction and showed inad-
equate sleep hygiene. This data suggests that central causes of
hypersomnia are important in this population, as has been re-
ported in other civilian TBI populations [42–44]. Baumann et al. re-
ported 38% of their 96-member TBI cohort (27% mTBI) had
subjective post-traumatic hypersomnia 6 months after head trau-
ma [43]. Although cerebrospinal fluid (CSF) hypocretin was found
to be low acutely, most of the patients’ CSF hypocretin levels re-
turned to normal 6 months after TBI. We found a higher prevalence
(60%) of hypersomnia many years after mTBIs, making direct com-
parisons difficult but suggesting that hypersomnia may remain a
persistent complaint. As most of our patients presented with mul-
tiple and mixed aetiology head injury, it is conceivable that dam-
age to the hypothalamus with loss of hypocretin neurons and
damage to other diffusely distributed arousal systems may have
occurred as a consequence of shear stress/diffuse axonal injury
sometimes seen in closed head injury [45].
4.2. Co-morbid sleep disorders
Despite excluding other sleep disorders (moderate–severe SDB,
restless legs syndrome, and periodic limb movement disorder), co-
morbid sleep conditions were still prevalent in the insomnia
groups. Habitual snoring associated with mild obstructive SDB
events or REM sleep-related obstructive respiratory events was
common (29%) in patients with insomnia; however, we did not
find differences in SDB prevalence between insomnia groups.
These sleep-related respiratory events can occur in the sleep–wake
transition, adding to sleep onset difficulties or precipitate middle
Table 3
Data represented as frequency (%). Post hoc significance levels are labeled as follows:
HS (n = 6) PTSD (n = 9) PTSD–mTBI
(n = 15)
Sleep disorders (n, %)
SDB (AHI P5) 0 1 (11) 4 (27)
Parasomnias
Confusional arousals 0 4 (44) 4 (27)
Sleepwalking 0 2 (22) 3 (20)
SRED 0 1 (11) 1 (7)
RBD 0 1 (11) 3 (20)
Sleep-related
hallucinations
0 3 (33) 2 (13)
Nightmares 1 (17) a 8 (89) 12 (80)
Sleep-related movement disorders
Bruxism 2 (33) 6 (67) 12 (80)
RLS 0 2 (22) 2 (13)
PLMS 0 1 (11) 1 (7)
SDB, sleep disordered breathing; AHI, apnoea-hypopnea index; SRED, sleep-related
eating disorder; RBD, REM sleep behaviour disorder; RLS, restless legs syndrome;
PLMS, periodic limb movements in sleep.
a p < 0.05 for comparison between HS and both insomnia groups.
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of the night awakenings, contributing to maintenance insomnia
complaints. In addition, REM and NREM sleep parasomnias were
common (38% of participants) in both insomnia groups. These
may be a consequence of psychotropic medications, untreated
SDB, stress, chronic sleep deprivation, or a combination of these.
These findings are in accord with published increased prevalence
rates of parasomnia after TBI and in psychiatric populations
[42,46]. Nightmares, reenacting dreams concerning combat, an
inherent symptom of PTSD, were significantly more common in
both insomnia groups. Our results are consistent with the reported
association of frequent nightmares and severe difficulties with ini-
tiating and maintaining sleep in this veteran population [47].
4.3. PSG
PSG revealed a number of differences between the insomnia
groups and the HS group in sleep continuity variables including
lower SE and increased SOL, awakenings and arousal index. The
PTSD group also had higher WASO compared with the HS and
PTSD–mTBI groups. As far as sleep architecture is concerned, both
insomnia groups had increased proportional N1 sleep, a marker of
greater sleep fragmentation, in accordance with previous reports in
post-TBI and PTSD-associated insomniacs [17,19].
4.4. ACT/SDs
With the exception of TIB, most sleep variables were signifi-
cantly different between patients with insomnia and HS. Sleep con-
tinuity variables were worse in the PTSD group compared with
PTSD–mTBI insomniacs. The PTSD–mTBI group had significantly
decreased ACT–WASO as compared to the PTSD group. This pattern
was also seen in the SD but did not reach statistical significance be-
tween the groups.
Our results are largely in agreement with most previous inves-
tigations employing ACT, PSG, and SDs in insomnia of differing
aetiologies [18,48–50]. Although ACT WASO and TST correlated
well with PSG parameters for insomniacs and HSs on one night
of PSG, ACT SOL was not well correlated with PSG SOL for insomni-
acs. This is not surprising as PSG and ACT measure different sleep
physiology constructs: the former measures EEG-defined sleep on-
set while the latter estimates sleep onset based on absence of
movement. As compared with PSG, ACT in insomnia tends to over-
estimate total sleep duration and underestimate SOL, as it cannot
detect motionless wakefulness [48,49].
Our ACT and home SD results corroborated many of the results
of in-lab PSG. Despite some of the limitations mentioned above, we
believe home ACT and SD sleep parameters are valid general esti-
mates of the sleep of insomniacs in their home environment. A re-
cent study in primary insomnia and normal sleepers correlating
portable home PSG recordings with wrist ACT on three consecutive
nights showed that estimates of WASO, TST, and SE did not differ
significantly from each other across nights [50]. Medium to large
correlations were found between most of the PSG and ACT sleep
measures. An actigraph with a photodiode detector was useful in
discovering nocturnal habits that may not have been reported
otherwise (i.e., subjects sleeping with television on all night or
use of portable electronic devices during awakenings). ACT may
provide approximations of home sleep in insomniacs using this
specific model and settings. Although SD may provide similar sleep
estimations, young veterans may fail to faithfully complete SDs.
Thus, ACT provides a valuable option for relatively low-cost, reli-
able, and objective prolonged assessment of sleep/wake patterns
in the veteran’s usual sleep environment.
One of the novel findings of our investigation was that signifi-
cantly lowerWASO was seen in the PTSD–mTBI group as compared
to the PTSD group in multiple measures (PSG and home ACT). This
relationship was also noted on the home SD but it did not reach
statistical significance. One possible explanation for the lower
PSG WASO observed in the PTSD–mTBI group is that post-trau-
matic hypersomnia in these subjects may partially help consoli-
date nighttime sleep. However, it is unclear if lower WASO in the
PTSD–mTBI insomniacs is of clinical significance as both insomnia
groups had similar rates of insomnia severity and subjective sleep
quality.
Table 4
Data presented as medians (interquartile range). Post hoc significance levels are labeled as follows:
HS (A) (n = 6) PTSD (B) (n = 9) PTSD–mTBI (C) (n = 15) Cliff’s delta (d)
AxB AxC BxC
PSG measures
Sleep initiation and maintenance
Total sleep time (min) 386 (35) a 318 (38) 309 (95) 0.74 0.1 0.08
Sleep efficiency (%) 96 (2) a 85 (14) 90 (12) 0.96 0.47 0.32
Sleep onset latency (min) 7 (13) a 18 (23) 22 (31) 0.72 0.78 0.1
Wake after sleep onset (min) 11 (10) b 49 (35) 15 (41) c 0.85 0.34 0.46
No. of awakening 6 (4) a 17 (14) 13 (15) 0.69 0.68 0.07
Arousals index (arousals/h) 1.7 (0) a 6.3 (8) 6.1 (7) 1 0.87 0.01
Sleep architecture
% of N1 sleep 5 (1) a 10 (6) 10 (7) 0.82 1 0.01
% of N2 sleep 53 (5) 54 (19) 55 (24) 0.15 0.24 0.08
% of N3 sleep 18 (4) 15 (14) 12 (14) 0.67 0.62 0.08
% of REM sleep 21 (6) 19 (7) 18 (10) 0.44 0.56 0.11
REM latency (min) 77 (11) 106 (51) 101 (39) 0.3 0.68 0.05
Respiratory and motor events
AHI (/hour) 0.8 (1) 0.6 (2) 2.7 (8) 0.17 0.36 0.37
PLMSI (/hour) 1.3 (9) 0 (1) 2.6 (6) 0.37 0.04 0.38
Post-PSG diary
Total sleep time (min) 398 (23) a 290 (32) 302 (89) 0.98 0.83 0.09
Sleep efficiency (%) 97 (2) a 81 (12) 84 (12) 1 0.96 0.26
Sleep onset latency (min) 8 (9) a 33 (26) 30 (36) 1 0.97 0.05
Wake after sleep onset (min) 10 (9) a 65 (33) 30 (45) c 1 0.89 0.61
PSG, polysomnography; AHI, apnoea-hypopnea index; PLMSI, periodic limb movements in sleep index.
a p < 0.05 for comparison between HS and both insomnia groups;
b p < 0.05 for comparison between HS and either PTSD or PTSD–mTBI;
c p < 0.05 for comparisons between PTSD and PTSD–mTBI.
 Effect size estimate: d = 0.147 (small); d = 0.33 (moderate); and d = 0.474 (large).
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All of the significant differences between the groups were
accompanied by large effect sizes. Value distributions between
groups were disparate and differences large enough to be detected
despite small sample sizes.
4.5. Insomnia aetiology
Insomnia aetiology in this veteran population is complex and
there are multiple interacting aetiologies for the sleep difficulties
veterans experience upon returning to civilian life. War-specific
demands increase veteran’s risk for insomnia including crowded
sleeping conditions, loud noise exposure, and the emergence of
poor sleep habits imposed by irregular sleep–wake schedules
[51]. Soldiers often sleep when they can, engaging in daytime nap-
ping, with these habits entrenched during deployments. For exam-
ple, most of our insomniacs reported shift work history during
military service. In a cross-sectional study of 156 deployed Air
Force personnel, more than 40% of them fulfilled chronic insomnia
criteria using SDs and three-quarters reported worsened sleep
quality during deployment [51]. In a recent large longitudinal co-
hort study in this population, deployed, or post-deployed person-
nel reported shorter adjusted sleep duration and higher odds of
sleeping difficulties compared with those who had not been de-
ployed [13]. Those reporting mental health symptoms and combat
exposure had higher odds of sleeping difficulties suggesting that
these variables mediate sleeping problems during and after
deployment. Furthermore, disrupted sleep following recent trauma
exposure predicts the development of PTSD [22]. Upon returning
home, psychosocial stressors can result in emotional arousals, ten-
sion, and rumination, adding further to sleeping difficulties.
Inadequate sleep hygiene was common in both insomnia
groups, evidenced by daytime napping, excessive caffeine intake,
and oversleeping on weekends. Surfing the Internet and nocturnal
exercise were reported as strategies of ‘exhausting’ oneself to
sleep. Recent studies in active military personnel have noted sim-
ilar activities incongruent with sleep onset during deployment
[51]. These may be reinforced after military separation by difficul-
ties in finding schooling or employment with steady schedules.
One recent multifaceted treatment trial combining cognitive
behavioural therapy and image rehearsal therapy targeting sleep
hygiene irregularities and co-morbid nightmares has been shown
to be successful in the OEF/OIF veterans with PTSD [52].
Mood, anxiety, and substance abuse disorders may be conse-
quences of chronic insomnia as well as potential causes of insom-
nia in OEF/OIF veterans [4,47]. A chart review of outpatient OEF/
OIF veterans describing the relationship between the polytrauma
clinical triad (pain, PTSD, and TBI) and insomnia found that PTSD
and pain, but not mTBI, were significantly associated with insom-
nia [4]. However, in contrast to our study, this series did note that
insomnia was more severe in patients with PTSD and co-morbid
mTBI. Similarly, in people who have a history of mTBI, the presence
of PTSD has been shown to increase the risk for persistent post-
concussive symptoms including insomnia [53]. Although subjects
in whom pain was a significant contributor to insomnia were ex-
cluded, it is likely that insomnia was partially mediated by PTSD
and depression symptoms.
4.6. Study limitations
Our study has several methodological limitations, the most
important of which is using the participant’s account to diagnose
mTBI years after the incidents. In most cases, military medical re-
cords were not available to corroborate the history. Self-report
may have resulted in misdiagnosis of mTBI, especially in veterans
with potential secondary gain. Second, in our laboratory PSG, we
awakened subjects earlier than their usual home waking times,
which likely affected their TST and sleep architecture. Third, partic-
ipants were allowed to continue using psychotropic/hypnotic med-
ications which affect sleep parameters; thus, some differences (or
lack thereof) between the groups may have been mediated by
medications. Withdrawal of these medications may have un-
masked other differences between the groups as psychotropic
medications (antidepressants and benzodiazepines) have varied
effects on sleep architecture [54]. Hypnotic medications may have
also influenced participant ability to subjectively predict sleeping
abnormalities, affected overscoring of ACT TST and parasomnia
prevalence [49]. However, we chose to allow medication use due
to its clinical relevance and potential recruitment difficulties. Most
Table 5
Data represented as medians (interquartile range). Post hoc significance levels are labeled as follows:
HS (A) (n = 6) PTSD (B) (n = 9) PTSD–mTBI (C) (n = 15) Cliff’s delta (d)
AxB AxC BxC
Actigraphy
Nights (total) 10 (1) 11 (5) 13 (3)
Sleep onset time 23:08 b 00:18 00:49 0.63 0.68 0.16
Sleep offset time 06:27 a 08:00 08:33 0.48 0.82 0.14
Time in bed (min) 463 (35) 475 (28) 502 (60) 0.3 0.6 0.33
Total sleep time (min) 433 (37) a 365 (45) 410 (49) 0.82 0.62 0.42
Sleep efficiency (%) 94 (2) a 78 (6) 84 (6) 1 1 0.35
Sleep onset latency (min) 9 (5) a 36 (22) 33 (14) 1 0.98 0.11
WASO (min) 20 (7) a 62 (13) 51 (23) c 1 1 0.54
NA P5 min (n) 1 (0.4) a 3 (0.8) 3 (1.4) 1 1 0.06
Fragmentation index (/h) 20 (7) a 46 (8) 36 (14) 1 0.96 0.42
Sleep diary
Time in bed (min) 455 (38) 467 (71) 485 (84) 0.26 0.26 0.06
Total sleep time (min) 428 (31) a 339 (77) 399 (55) 0.68 0.76 0.36
Sleep efficiency (%) 95 (1) a 72 (11) 77 (15) 1 1 0.2
Sleep onset latency (min) 8 (4) a 39 (20) 43 (21) 1 1 0.07
WASO (min) 18 (9) a 81 (28) 53 (29) 1 1 0.33
NA (n) 1 (0.3) a 3 (1) 2 (3) 0.78 0.71 0
Sleep quality 4 (0.2) a 2 (0.9) 3 (0.5) 1 1 0.12
WASO, wake after sleep onset; NA, nocturnal awakenings.
a p < 0.05 for comparison between HS and both insomnia groups;
b p < 0.05 for comparison between HS and PTSD–mTBI;
c p < 0.05 for comparison between PTSD and PTSD–mTBI.
 Effect size estimate: d = 0.147 (small); d = 0.33 (moderate); and d = 0.474 (large).
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insomnia subjects reported improved sleep quality during the in-
lab PSG, which may have also dampened existing differences. Time
duration between deployment and sleep assessment makes identi-
fying the insomnia aetiology difficult. We were unable to recruit
veterans with insomnia and mTBI alone without any psychiatric
symptoms; therefore, we could not determine the independent im-
pact of TBI on sleep complaints. This is partially related to the fact
that the Miami VA Medical Center is a third-tier trauma centre and
subjects are not evaluated until about 1 year after military separa-
tion. Therefore, most patients who suffered mTBIs have recuper-
ated by the time they enter the VA system [5]. Patients who
suffered mTBI and also have psychiatric symptoms may be most
likely to seek medical treatment. All participants were male so that
our findings may not extend to female veterans, who often report
worse insomnia symptoms [13]. Our study does not allow us to
determine what percentage of insomnia is related to PTSD, depres-
sion, mTBI, or inadequate sleep hygiene established during deploy-
ment. Finally, due to limited statistical power, we cannot exclude
modest differences between the groups.
Our study suggests that insomnia in OEF/OIF veterans with
PTSD or PTSD–mTBI share some clinical, PSG, and ACT characteris-
tics with those of primary insomnia. The significant differences be-
tween our insomnia groups included greater daytime sleepiness
and lower PSG and ACT WASO detected in the PTSD–mTBI group.
Veterans with insomnia may have a number of other sleep disor-
ders and sleep hygiene issues, which merit multifaceted assess-
ment and treatment. The American Academy of Sleep Medicine
(AASM) does not recommend PSG as part of the routine evaluation
of chronic insomnia patients but does endorse it in the setting of
suspected sleep-related breathing disorder, sleep-related move-
ment disorder, or sleep-related violent behaviours [55]. Given that
these co-morbid disorders may require independent treatment,
PSG should be considered in veterans with insomnia associated
with PTSD and/or mTBI. ACT may be a valuable complementary
tool in evaluating the sleep of young military veterans and assess-
ing their response to pharmacologic or behavioural treatment. Our
characterisation may help further define clinical approaches for
insomnia treatment; however, larger studies with subjects free of
psychotropic medications are needed to establish if other clinical
differences may exist in military veterans with insomnia.
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